Dina Burkitbayeva

Dina Burkitbayeva is a leading entrepreneur and investor within the neuropsychiatric space. She currently serves as both the Co-Founder and CEO of Freedom Biosciences, a biotechnology company developing next-generation psychedelic and ketamine-based therapeutics for depression and other mental-health conditions, and as Co-Founder of PsyMed Ventures, a venture fund investing in cutting-edge mental-health and neurotechnology innovations. She began her career at McKinsey & Company and J.P. Morgan before turning to entrepreneurship and investing at the intersection of neuroscience and mental health. Dina holds an MBA from Harvard Business School and along with a B.S. and B.A. in City & Regional Planning and Economics from Cornell University.

Jerrold Rosenbaum, MD

Dr. Jerrold Rosenbaum is a physician-scientist who is among the world’s leading authorities on mood and anxiety disorders, along with co-founding several neuropsychiatric biotechnology organizations. He currently serves as the Director of the Center for the Neuroscience of Psychedelics at the Massachusetts General Hospital (MGH), which seeks to understand how psychedelics impact the brain and elucidate potential therapeutic benefits of psychedelic therapies. He co-founded Sensorium, Psy Therapeutics, and Entheos Labs, organizations advancing innovative therapeutics within the neuropsychiatric space. In addition, Dr. Rosenbaum is the Stanley Cobb Professor of Psychiatry at Harvard Medical School and Psychiatrist‐in-Chief Emeritus of the Department of Psychiatry at MGH, where he led the department for two decades and oversaw hundreds of clinicians, researchers and trainees. Dr. Rosenbaum received his undergraduate degree from Yale College and his medical degree from Yale School of Medicine. He completed his residency and fellowship in Psychiatry at Massachusetts General Hospital, Harvard Medical School.

Alexa Tucker

Alexa Tucker is currently a first-year student in the MS/MBA in Biotechnology dual degree program at HBS/Harvard GSAS. Alexa began her career in life sciences strategy consulting at ClearView Healthcare Partners before transitioning into the biopharmaceutical industry in a business development role at Alkermes. Alexa became interested in the unique opportunities and barriers facing novel drug development in the neuropsychiatric space while evaluating opportunities for potential in-licensing or acquisition at Alkermes. Alexa holds a B.A. from Dartmouth College.